Capacitation induces changes in metabolic pathways supporting motility of epididymal and ejaculated sperm

Autor: Melanie Balbach, Lubna Ghanem, Sara Violante, Aye Kyaw, Ana Romarowski, Justin R. Cross, Pablo E. Visconti, Lonny R. Levin, Jochen Buck

Publikováno v: Frontiers in Cell and Developmental Biology, Vol 11 (2023)

Mammalian sperm require sufficient energy to support motility and capacitation for successful fertilization. Previous studies cataloging the changes to metabolism in sperm explored ejaculated human sperm or dormant mouse sperm surgically extracted fr

Externí odkaz: https://doaj.org/article/bf9504cd7458481db05ef83880ae9942

Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential

Autor: Thomas Rossetti, Jacob Ferreira, Lubna Ghanem, Hannes Buck, Clemens Steegborn, Robert W. Myers, Peter T. Meinke, Lonny R. Levin, Jochen Buck

Publikováno v: Frontiers in Physiology, Vol 13 (2022)

In mammalian cells, 10 different adenylyl cyclases produce the ubiquitous second messenger, cyclic adenosine monophosphate (cAMP). Amongst these cAMP-generating enzymes, bicarbonate (HCO3−)-regulated soluble adenylyl cyclase (sAC; ADCY10) is unique

Externí odkaz: https://doaj.org/article/79059c54d75b4a94ab021be7ad8ea4df

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape

Autor: Sanne B. Jensen, Jens Bukh, Ulrik Fahnøe, Stéphanie B. N. Serre, Kristian Schønning, Martin Schou Pedersen, Santseharay Ramirez, Judith M. Gottwein, Lubna Ghanem, Qi Tang, Daryl Humes, Long V. Pham

Publikováno v: Journal of Hepatology. 70:388-397

Background & Aims Protease inhibitors (PIs) are of central importance in the treatment of patients with chronic hepatitis C virus (HCV) infection. HCV NS3 protease (NS3P) position 80 displays polymorphisms associated with resistance to the PI simepre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f1ebcbaf83bd914d30eabf131072fb8
https://doi.org/10.1016/j.jhep.2018.10.031

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Autor: Jean-Michel Pawlotsky, Sanne B. Jensen, Henrik Krarup, Christina Sølund, Daryl Humes, Stéphanie B. N. Serre, Christoph Sarrazin, Santseharay Ramirez, Jonathan Filskov, Judith M. Gottwein, Long V. Pham, Jens Bukh, Anne Finne Pihl, Lubna Ghanem, Julia Dietz, Slim Fourati, Ulrik Fahnøe, Nina Weis, Kristian Schønning, Qi Tang, Martin Schou Pedersen

Publikováno v: Hepatology (Baltimore, Md.)
Jensen, S B, Fahnøe, U, Pham, L V, Serre, S, Tang, Q, Ghanem, L, Pedersen, M S, Ramirez, S, Humes, D, Pihl, A F, Filskov, J, Sølund, C S, Dietz, J, Fourati, S, Pawlotsky, J-M, Sarrazin, C, Weis, N, Schønning, K, Krarup, H, Bukh, J & Gottwein, J M 2019, ' Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants ', Hepatology, vol. 70, no. 3, pp. 771-787 . https://doi.org/10.1002/hep.30647
Jensen, S B, Fahnøe, U, Pham, L V, Serre, S B N, Tang, Q, Ghanem, L, Pedersen, M S, Ramirez, S, Humes, D, Pihl, A F, Filskov, J, Sølund, C S, Dietz, J, Fourati, S, Pawlotsky, J M, Sarrazin, C, Weis, N, Schønning, K, Krarup, H, Bukh, J & Gottwein, J M 2019, ' Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants ', Hepatology, vol. 70, no. 3, pp. 771-787 . https://doi.org/10.1002/hep.30647

Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b70b1b4572a0285d017fd5f82a4dea0
https://pubmed.ncbi.nlm.nih.gov/30964552

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle

Autor: Daryl Humes, Henrik Krarup, Jens Bukh, Sanne B. Jensen, Yi-Ping Li, Stéphanie B. N. Serre, Santseharay Ramirez, Judith M. Gottwein, Lubna Ghanem

Publikováno v: Serre, S B N, Jensen, S B, Ghanem, L, Humes, D G, Ramirez, S, Li, Y-P, Krarup, H, Bukh, J & Gottwein, J M 2016, ' Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants : In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle ', Antimicrobial Agents and Chemotherapy, vol. 60, no. 6, pp. 3563-3578 . https://doi.org/10.1128/AAC.02929-15

Hepatitis C virus (HCV) NS3 protease inhibitors (PIs) are important components of novel HCV therapy regimens. Studies of PI resistance initially focused on genotype 1. Therefore, knowledge about the determinants of PI resistance for the highly preval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2e7e231e0002d50a63c8fa93892dc08
https://pubmed.ncbi.nlm.nih.gov/27021330